A new study provides important insight into how amyloid-beta and tau proteins impact brain activity and possibly contribute to cognitive decline in Alzheimer's disease.
HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700, for the potential treatment of KRAS mutated cancers. KRAS mutations are most frequently found ...
LEHI, Utah, Sept. 23, 2024 /PRNewswire/ -- Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company advancing novel therapies for inflammation-related diseases, today announced ...
(NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the direct CNS anti-inflammatory ...